Ironwood Pharmaceuticals

IRWD60

Penny Stock

$4.52arrow_drop_up0.89%$0.04

Penny Stock

IRWD60

$4.52

arrow_drop_up0.89%$0.04

Penny Stock

Performance History

Key Stats
Open	$4.48
Prev. Close	$4.48
EPS	0.08
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$715.63M

	LOW	HIGH
Day Range	4.47	4.68
52 Week Range	3.79	15.70

Ratios







EPS	0.08

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals Inc (IRWD) is a pharmaceutical company focused on developing and commercializing innovative medicines. The company has a strong track record of bringing important treatments to patients in areas of significant unmet need. With a market cap of over $1 billion, Ironwood is a prominent player in the pharmaceutical industry.

Ironwood Pharmaceuticals Inc is known for its expertise in gastrointestinal disorders, particularly in the development of therapies for irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD). The company's flagship product, LINZESS, is approved for the treatment of both IBS and chronic idiopathic constipation. LINZESS has been a major success for Ironwood, generating significant revenue and establishing the company as a leader in the field.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Thomas A. McCourt
Headquarters: Boston
Employees: 219
Exchange: NASDAQ

add Ironwood Pharmaceuticals to watchlist

Keep an eye on Ironwood Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Ironwood Pharmaceuticals (IRWD)?

Ironwood Pharmaceuticals (IRWD) has a market capitalization of $715.63M. The average daily trading volume is 1.95M, indicating the stock's liquidity and investor engagement.

help

What is Ironwood Pharmaceuticals 's (IRWD) price per share?

The current price per share for Ironwood Pharmaceuticals (IRWD) is $4.52. The stock has seen a price change of $0.04 recently, indicating a 0.89% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Ironwood Pharmaceuticals (IRWD)?

For Ironwood Pharmaceuticals (IRWD), the 52-week high is $15.7, which is 247.35% from the current price. The 52-week low is $3.79, the current price is 19.26% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Ironwood Pharmaceuticals (IRWD) a growth stock?

Ironwood Pharmaceuticals (IRWD) has shown an average price growth of 0.41% over the past three years. It has received a score of 39 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Ironwood Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Ironwood Pharmaceuticals (IRWD) stock price performance year to date (YTD)?

As of the latest data, Ironwood Pharmaceuticals (IRWD) has a year-to-date price change of -63.58%. Over the past month, the stock has experienced a price change of -5.04%. Over the last three months, the change has been -20.7%. Over the past six months, the figure is -46.89%. Looking at a longer horizon, the five-year price change stands at -52.52%.

help

Is Ironwood Pharmaceuticals (IRWD) a profitable company?

Ironwood Pharmaceuticals (IRWD) has a net income of -$1B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 29.07% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $442.74M, with a revenue growth rate of 7.83%, providing insight into the company's sales performance and growth. The gross profit is $441.16M. Operating income is noted at $209.04M. Furthermore, the EBITDA is $134.36M.